

# Ralph A Defronzo

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6502131/ralph-a-defronzo-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

214  
papers

20,935  
citations

59  
h-index

144  
g-index

228  
ext. papers

23,774  
ext. citations

10.4  
avg, IF

7.14  
L-index

#	Paper	IF	Citations
214	Insulin: The master regulator of glucose metabolism.. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 155142	12.7	6
213	Dapagliflozin Impairs the Suppression of Endogenous Glucose Production in Type 2 Diabetes Following Oral Glucose.. <i>Diabetes Care</i> , <b>2022</b> ,	14.6	1
212	Prandial hepatic glucose production during hypoglycemia is altered after gastric bypass surgery and sleeve gastrectomy.. <i>Metabolism: Clinical and Experimental</i> , <b>2022</b> , 131, 155199	12.7	0
211	The Insulin-Sensitizer Pioglitazone Remodels Adipose Tissue Phospholipids in Humans.. <i>Frontiers in Physiology</i> , <b>2021</b> , 12, 784391	4.6	0
210	Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage Infiltration. <i>Diabetes</i> , <b>2021</b> , 70, 1303-1316	0.9	3
209	Therapeutic Manipulation of Myocardial Metabolism: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 2022-2039	15.1	7
208	Insulin secretion is a strong predictor for need of insulin therapy in patients with new-onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1631-1639	6.7	1
207	Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. <i>Diabetes Care</i> 2020;43:2296-2302. <i>Diabetes Care</i> , <b>2021</b> , 44, e98-e99	14.6	1
206	Determinants of penetrance and variable expressivity in monogenic metabolic conditions across 77,184 exomes. <i>Nature Communications</i> , <b>2021</b> , 12, 3505	17.4	5
205	Ultrasound-Targeted Microbubble Destruction Mediates Gene Transfection for Beta-Cell Regeneration and Glucose Regulation. <i>Small</i> , <b>2021</b> , 17, e2008177	11	4
204	Effect of Mild Physiologic Hyperglycemia on Insulin Secretion, Insulin Clearance, and Insulin Sensitivity in Healthy Glucose-Tolerant Subjects. <i>Diabetes</i> , <b>2021</b> , 70, 204-213	0.9	4
203	Adaptation of Insulin Clearance to Metabolic Demand Is a Key Determinant of Glucose Tolerance. <i>Diabetes</i> , <b>2021</b> , 70, 377-385	0.9	17
202	Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT. <i>Diabetes Care</i> , <b>2021</b> , 44, 433-439	14.6	7
201	Association of Baseline Characteristics With Insulin Sensitivity and $\beta$ Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. <i>Diabetes Care</i> , <b>2021</b> , 44, 340-349	14.6	3
200	Pioglitazone corrects dysregulation of skeletal muscle mitochondrial proteins involved in ATP synthesis in type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>2021</b> , 114, 154416	12.7	6
199	Serum carotenoids and Pediatric Metabolic Index predict insulin sensitivity in Mexican American children. <i>Scientific Reports</i> , <b>2021</b> , 11, 871	4.9	0
198	Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. <i>Nature Reviews Nephrology</i> , <b>2021</b> , 17, 319-334	14.9	59

197	Impaired Suppression of Glucagon in Obese Subjects Parallels Decline in Insulin Sensitivity and Beta-Cell Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 1398-1409	5.6	4
196	Proximal tubular epithelial insulin receptor mediates high-fat diet-induced kidney injury. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	3
195	Accuracy of 1-Hour Plasma Glucose During the Oral Glucose Tolerance Test in Diagnosis of Type 2 Diabetes in Adults: A Meta-analysis. <i>Diabetes Care</i> , <b>2021</b> , 44, 1062-1069	14.6	9
194	Preface: Cardiorenal Considerations for Type 2 Diabetes-Time to Exit the Dark Ages. <i>Diabetes Spectrum</i> , <b>2021</b> , 34, 214-215	1.9	
193	Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2113-2125	4	
192	New Insights on the Interactions Between Insulin Clearance and the Main Glucose Homeostasis Mechanisms. <i>Diabetes Care</i> , <b>2021</b> , 44, 2115-2123	14.6	5
191	Sodium-Glucose Cotransporter 2 Inhibitors and the Kidney. <i>Diabetes Spectrum</i> , <b>2021</b> , 34, 225-234	1.9	0
190	Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion. <i>Diabetes Care</i> , <b>2020</b> , 43, 1065-1069	14.6	8
189	Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors. <i>Diabetes</i> , <b>2020</b> , 69, 681-688	0.9	11
188	Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA <sub>1c</sub> , in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 1234-1241	14.6	18
187	Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children. <i>PLoS ONE</i> , <b>2020</b> , 15, e0240467	3.7	4
186	Newly Discovered Abnormal Glucose Tolerance in Patients With Acute Myocardial Infarction and Cardiovascular Outcomes: A Meta-analysis. <i>Diabetes Care</i> , <b>2020</b> , 43, 1958-1966	14.6	9
185	Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin. <i>Diabetes Care</i> , <b>2020</b> , 43, 2519-2527	14.6	1
184	Improved Beta Cell Glucose Sensitivity Plays Predominant Role in the Decrease in HbA <sub>1c</sub> with Cana and Lira in T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	2
183	Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy. <i>Diabetologia</i> , <b>2020</b> , 63, 2423-2433	10.3	7
182	Culture on a native bone marrow-derived extracellular matrix restores the pancreatic islet basement membrane, preserves islet function, and attenuates islet immunogenicity. <i>FASEB Journal</i> , <b>2020</b> , 34, 8044-8056	0.9	3
181	Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children <b>2020</b> , 15, e0240467		
180	Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children <b>2020</b> , 15, e0240467		

179	Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children <b>2020</b> , 15, e0240467		
178	Acanthosis nigricans as a composite marker of cardiometabolic risk and its complex association with obesity and insulin resistance in Mexican American children <b>2020</b> , 15, e0240467		
177	Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	2
176	Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents. <i>Endocrine Reviews</i> , <b>2019</b> , 40, 1447-1467	27.2	85
175	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. <i>Diabetes and Vascular Disease Research</i> , <b>2019</b> , 16, 133-143	3.3	63
174	Mild Physiologic Hyperglycemia Induces Hepatic Insulin Resistance in Healthy Normal Glucose-Tolerant Participants. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2842-2850	5.6	11
173	Exome sequencing of 20,791 cases of type 2 diabetes and 24,440 controls. <i>Nature</i> , <b>2019</b> , 570, 71-76	50.4	129
172	Exenatide regulates pancreatic islet integrity and insulin sensitivity in the nonhuman primate baboon <i>Papio hamadryas</i> . <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	8
171	Insulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 153-163	3.3	22
170	Genetic and environmental (physical fitness and sedentary activity) interaction effects on cardiometabolic risk factors in Mexican American children and adolescents. <i>Genetic Epidemiology</i> , <b>2018</b> , 42, 378-393	2.6	3
169	Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy. <i>Diabetes</i> , <b>2018</b> , 67, 1182-1189	0.9	36
168	Reduced skeletal muscle phosphocreatine concentration in type 2 diabetic patients: a quantitative image-based phosphorus-31 MR spectroscopy study. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2018</b> , 315, E229-E239	6	10
167	Ectopic BAT mUCP-1 overexpression in SKM by delivering a BMP7/PRDM16/PGC-1a gene cocktail or single PRMD16 using non-viral UTMD gene therapy. <i>Gene Therapy</i> , <b>2018</b> , 25, 497-509	4	6
166	Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, <i>Papio sp</i> . <i>PLoS ONE</i> , <b>2018</b> , 13, e0208757	3.7	2
165	Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance. <i>Diabetes</i> , <b>2018</b> , 67, 2507-2517	0.9	18
164	Combination Therapy With Exenatide Plus Pioglitazone Versus Basal/Bolus Insulin in Patients With Poorly Controlled Type 2 Diabetes on Sulfonylurea Plus Metformin: The Qatar Study. <i>Diabetes Care</i> , <b>2017</b> , 40, 325-331	14.6	26
163	Role of Adipose Tissue Insulin Resistance in the Natural History of Type 2 Diabetes: Results From the San Antonio Metabolism Study. <i>Diabetes</i> , <b>2017</b> , 66, 815-822	0.9	152
162	Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 809-813	6.7	44

161	Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes. <i>Diabetes</i> , <b>2017</b> , 66, 1999-2006	0.9	38
160	Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1353-1362	6.7	88
159	Efficacy of Exenatide Plus Pioglitazone Vs Basal/Bolus Insulin in T2DM Patients With Very High HbA1c. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 2162-2170	5.6	8
158	Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?. <i>Diabetes Care</i> , <b>2017</b> , 40, 813-820	14.6	78
157	Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves $\beta$ Cell Function in Subjects With Impaired Fasting Glucose. <i>Diabetes</i> , <b>2017</b> , 66, 2495-2502	0.9	12
156	CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , <b>2017</b> , 23, 207-238	3.2	302
155	Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. <i>Nature Reviews Nephrology</i> , <b>2017</b> , 13, 11-26	14.9	265
154	A Loss-of-Function Splice Acceptor Variant in Is Protective for Type 2 Diabetes. <i>Diabetes</i> , <b>2017</b> , 66, 2903-2914	2.9	32
153	Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes. <i>Diabetes Care</i> , <b>2017</b> , 40, 1530-1536	14.6	34
152	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm. <i>Diabetes Care</i> , <b>2017</b> , 40, 1121-1127	14.6	32
151	Sequence data and association statistics from 12,940 type 2 diabetes cases and controls. <i>Scientific Data</i> , <b>2017</b> , 4, 170179	8.2	22
150	The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies. <i>Diabetes Care</i> , <b>2016</b> , 39, 198-205	14.6	182
149	Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. <i>Hepatology</i> , <b>2016</b> , 64, 2028-2037	11.2	58
148	The genetic architecture of type 2 diabetes. <i>Nature</i> , <b>2016</b> , 536, 41-47	50.4	704
147	Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype. <i>Genomics Data</i> , <b>2016</b> , 8, 25-36		25
146	Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. <i>Diabetologia</i> , <b>2016</b> , 59, 1645-54	10.3	67
145	SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study. <i>Diabetes Care</i> , <b>2016</b> , 39, 717-25	14.6	211
144	Discordance Between Central (Brain) and Pancreatic Action of Exenatide in Lean and Obese Subjects. <i>Diabetes Care</i> , <b>2016</b> , 39, 1804-10	14.6	10

143	Dapagliflozin lowers plasma glucose concentration and improves $\beta$ cell function. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1927-32	5.6	97
142	Epidemiology and geography of type 2 diabetes mellitus <b>2015</b> , 29-51		0
141	Epidemiology and risk factors for type 1 diabetes mellitus <b>2015</b> , 17-28		2
140	Classification of diabetes mellitus and other categories of glucose intolerance <b>2015</b> , 1-16		11
139	Pathology of human diabetic neuropathy <b>2015</b> , 926-938		
138	Peripheral vascular and cerebrovascular disease in diabetes mellitus <b>2015</b> , 1091-1101		
137	Autonomic neuropathy <b>2015</b> , 939-952		
136	Erectile dysfunction in diabetes mellitus <b>2015</b> , 975-987		
135	Diabetic retinopathy and other ocular complications <b>2015</b> , 889-910		1
134	Clinical features and treatment of coronary heart disease in diabetes <b>2015</b> , 1064-1078		1
133	Periodontal disease and diabetes mellitus <b>2015</b> , 988-1004		
132	The economics of diabetes care: a global perspective <b>2015</b> , 1113-1124		4
131	Arterial hypertension in diabetes: etiology and treatment <b>2015</b> , 1079-1090		1
130	Hemostatic abnormalities in diabetes mellitus <b>2015</b> , 1051-1063		0
129	Connective tissue disorders in diabetes <b>2015</b> , 953-963		3
128	The diabetes challenge: from human and social rights to the empowerment of people with diabetes <b>2015</b> , 1103-1112		
127	Atherogenesis, coronary heart disease and insulin resistance syndrome in diabetes <b>2015</b> , 1031-1045		
126	Epidemiology of macrovascular disease and hypertension in diabetes mellitus <b>2015</b> , 1005-1030		3

125 Endothelial function and metabolic syndrome **2015**, 1046-1050

124 Treatment of obesity: bariatric surgery **2015**, 505-518

1

123 Pancreas and islet transplantation **2015**, 774-782

122 Glycated hemoglobin, serum proteins, and other markers as tools for monitoring **2015**, 853-871

1

121 Pathogenesis of diabetic microvascular complications **2015**, 873-888

120 Hypoglycemia and other complications of insulin therapy **2015**, 783-798

119 Psychological problems and management of patients with diabetes mellitus **2015**, 846-852

118 Type 2 diabetes in obese adolescents: pathophysiology and treatment **2015**, 815-822

117 Aging and diabetes mellitus **2015**, 836-845

1

116 New drugs for the treatment of diabetes mellitus **2015**, 709-725

115 Combination therapy in type 2 diabetes mellitus **2015**, 686-708

1

114 Diabetic ketoacidosis and hyperosmolar state **2015**, 799-814

3

113 Innovative therapies in diabetes: colesevelam and bromocriptine **2015**, 758-764

112 Implantable pumps and artificial and bio-artificial pancreas system **2015**, 765-773

111 Insulin pumps **2015**, 745-757

110 Incretin-based therapies **2015**, 726-744

109 PPAR agonists in the treatment of diabetes **2015**, 657-672

108  $\alpha$ -Glucosidase inhibitors **2015**, 673-685

8

- 107 Sulfonylureas and meglitinides: insights into physiology and translational clinical utility **2015**, 615-640 2
- 106 Metformin and other biguanides: pharmacology and therapeutic usage **2015**, 641-656 2
- 105 Prevention of diabetic microvascular complications **2015**, 564-573
- 104 Treatment of obesity: lifestyle and pharmacotherapy **2015**, 489-504
- 103 Animal models of obesity and type 2 diabetes **2015**, 519-528
- 102 The role of the hypothalamus in the maintenance of energy balance and peripheral glucose control **2015**, 529-537
- 101 Prevention of type 1 diabetes **2015**, 539-549
- 100 Prevention of type 2 diabetes **2015**, 550-563
- 99 Dietary management of diabetes mellitus in Europe and North America **2015**, 575-588
- 98 The role of energy metabolism in the regulation of energy balance **2015**, 479-488
- 97 The relationship between obesity and type 2 diabetes—the role of gut factors **2015**, 467-478
- 96 Pathogenesis of type 2 diabetes mellitus **2015**, 371-400 2
- 95  $\beta$ Cell mass and function in human type 2 diabetes **2015**, 354-370 3
- 94 Immunopathogenesis of type 1 diabetes in Western society **2015**, 442-453 0
- 93 Molecular genetics of type 1 diabetes **2015**, 454-466
- 92 Monogenic disorders of the  $\beta$ cell **2015**, 426-441
- 91 Glucose toxicity **2015**, 413-425 3
- 90 The genetics of type 2 diabetes **2015**, 401-412



89	The insulin resistance syndrome <b>2015</b> , 337-353	0
88	Diabetes and sleep apnea <b>2015</b> , 316-336	7
87	Type 2 diabetes and cancer <b>2015</b> , 306-315	
86	Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) <b>2015</b> , 292-305	1
85	Pathogenesis of nonalcoholic fatty liver disease (NAFLD) <b>2015</b> , 281-291	1
84	Mechanisms of insulin signal transduction <b>2015</b> , 161-192	1
83	Metabolomics: applications in type 2 diabetes mellitus and insulin resistance <b>2015</b> , 275-280	0
82	Insulin actions in vivo: glucose metabolism <b>2015</b> , 211-233	5
81	Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals <b>2015</b> , 262-274	
80	Measuring insulin action in vivo <b>2015</b> , 234-249	
79	Protein metabolism in health and diabetes <b>2015</b> , 250-261	0
78	Regulation of glucose metabolism in liver <b>2015</b> , 193-210	1
77	Incretin physiology in health and disease <b>2015</b> , 145-159	
76	Biosynthesis, secretion, and action of glucagon <b>2015</b> , 136-144	
75	Neuropeptides and islet hormone secretion <b>2015</b> , 125-135	
74	Normal $\beta$ cell function <b>2015</b> , 108-124	2
73	$\beta$ Cell biology of insulin secretion <b>2015</b> , 96-107	1
72	Insulin gene expression and biosynthesis <b>2015</b> , 82-95	1

71	Pancreatic morphology in normal and diabetic states <b>2015</b> , 69-81		1
70	Development and maintenance of the islet $\beta$ cell <b>2015</b> , 53-68		1
69	Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. <i>American Journal of Physiology - Renal Physiology</i> , <b>2015</b> , 309, F889-900	4.3	82
68	Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2819-33	4	15
67	Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates. <i>American Journal of Pathology</i> , <b>2015</b> , 185, 139-50	5.8	12
66	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , <b>2015</b> , 1, 15019	51.1	651
65	Transcriptomic identification of ADH1B as a novel candidate gene for obesity and insulin resistance in human adipose tissue in Mexican Americans from the Veterans Administration Genetic Epidemiology Study (VAGES). <i>PLoS ONE</i> , <b>2015</b> , 10, e0119941	3.7	33
64	Nox2 mediates skeletal muscle insulin resistance induced by a high fat diet. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 13427-39	5.4	52
63	Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin. <i>Diabetes Care</i> , <b>2015</b> , 38, 384-93	14.6	210
62	Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney. <i>American Journal of Physiology - Cell Physiology</i> , <b>2014</b> , 306, C202-11	5.4	14
61	APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. <i>Cell Reports</i> , <b>2014</b> , 7, 1227-38	10.6	90
60	Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. <i>Journal of Clinical Investigation</i> , <b>2014</b> , 124, 509-14	15.9	514
59	Successful $\beta$ cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1. <i>Cell Cycle</i> , <b>2014</b> , 13, 1145-51	4.7	29
58	The disposition index does not reflect $\beta$ cell function in IGT subjects treated with pioglitazone. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 3774-81	5.6	25
57	Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. <i>Diabetes Care</i> , <b>2014</b> , 37, 1706-11	14.6	11
56	Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlates. <i>Diabetes</i> , <b>2013</b> , 62, 3920-60.9		68
55	Mechanisms of glucose lowering of dipeptidyl peptidase-4 inhibitor sitagliptin when used alone or with metformin in type 2 diabetes: a double-tracer study. <i>Diabetes Care</i> , <b>2013</b> , 36, 2756-62	14.6	43
54	Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2013</b> , 33, 393-9	9.4	78

53	In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S162-74	14.6	72
52	Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. <i>Diabetes Care</i> , <b>2013</b> , 36, 3169-76	14.6	193
51	Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans. <i>Diabetes</i> , <b>2013</b> , 62, 3324-8	0.9	163
50	Distinct cell defects in impaired fasting glucose and impaired glucose tolerance. <i>Diabetes</i> , <b>2012</b> , 61, 447-53	0.9	88
49	Pioglitazone for diabetes prevention in impaired glucose tolerance. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1104-15	59.2	537
48	Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose. <i>Acta Diabetologica</i> , <b>2011</b> , 48, 209-17	3.9	46
47	Role of glycated hemoglobin in the prediction of future risk of T2DM. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 2596-600	5.6	35
46	Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. <i>Endocrine Reviews</i> , <b>2011</b> , 32, 515-31	27.2	292
45	Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. <i>Diabetes Care</i> , <b>2010</b> , 33, 951-7	14.6	90
44	Pathogenesis of insulin resistance in skeletal muscle. <i>Journal of Biomedicine and Biotechnology</i> , <b>2010</b> , 2010, 476279		325
43	Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 1916-23	5.6	64
42	Genome-wide linkage scan for genes influencing plasma triglyceride levels in the Veterans Administration Genetic Epidemiology Study. <i>Diabetes</i> , <b>2009</b> , 58, 279-84	0.9	21
41	Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 13992-7	11.5	125
40	Predictive models of insulin resistance derived from simple morphometric and biochemical indices related to obesity and the metabolic syndrome in baboons. <i>Cardiovascular Diabetology</i> , <b>2009</b> , 8, 22	8.7	24
39	Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. <i>Diabetes</i> , <b>2009</b> , 58, 773-95	0.9	1832
38	Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range. <i>Diabetes Care</i> , <b>2008</b> , 31, 311-5	14.6	29
37	Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2008</b> , 294, E846-52	6	132
36	Physiological and molecular determinants of insulin action in the baboon. <i>Diabetes</i> , <b>2008</b> , 57, 899-908	0.9	71

35	Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 2943-52	2.5	321
34	Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. <i>Gastroenterology</i> , <b>2007</b> , 133, 496-506	13.3	397
33	Thiazolidinediones improve beta-cell function in type 2 diabetic patients. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2007</b> , 292, E871-83	6	145
32	The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2007</b> , 92, 1249-55	5.6	207
31	What is the best predictor of future type 2 diabetes?. <i>Diabetes Care</i> , <b>2007</b> , 30, 1544-8	14.6	258
30	Exenatide: first-in-class incretin mimetic for the treatment of Type 2 diabetes mellitus. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2006</b> , 1, 329-341	4.1	18
29	Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. <i>Diabetes</i> , <b>2006</b> , 55, 1430-5	0.9	384
28	A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 2297-307	59.2	1311
27	Contributions of beta-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. <i>Diabetes Care</i> , <b>2006</b> , 29, 1130-9	14.6	262
26	Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. <i>Diabetes</i> , <b>2005</b> , 54, 3148-53	0.9	146
25	beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2005</b> , 90, 493-500	5.6	407
24	A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. <i>Diabetes</i> , <b>2003</b> , 52, 2461-74	0.9	388
23	Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients. <i>Diabetes</i> , <b>2003</b> , 52, 1943-50	0.9	116
22	Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. <i>Metabolism: Clinical and Experimental</i> , <b>2002</b> , 51, 1111-9	12.7	67
21	Time course of insulin action on tissue-specific intracellular glucose metabolism in normal rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1998</b> , 274, E642-50	6	8
20	Effect of hyperinsulinemia on plasma leptin concentrations and food intake in rats. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>1998</b> , 274, E998-E1001	6	16
19	Reciprocal Variations in Insulin-Stimulated Glucose Uptake and Pancreatic Insulin Secretion in Women With Normal Glucose Tolerance. <i>Journal of the Society for Gynecologic Investigation</i> , <b>1995</b> , 2, 708-715		27
18	Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. <i>New England Journal of Medicine</i> , <b>1995</b> , 333, 541-9	59.2	1049

17	Effect of insulin and plasma amino acid concentration on leucine metabolism in cirrhosis. <i>Hepatology</i> , <b>1991</b> , 14, 432-441	11.2	37
16	Measurement of abdominal fat with T1-weighted MR images. <i>Journal of Magnetic Resonance Imaging</i> , <b>1991</b> , 1, 363-9	5.6	58
15	Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. <i>New England Journal of Medicine</i> , <b>1991</b> , 324, 1626-32	59.2	150
14	Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1991</b> , 73, 1294-301	5.6	317
13	Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. <i>Diabetes Care</i> , <b>1991</b> , 14, 173-94	14.6	3010
12	Effect of insulin and plasma amino acid concentration on leucine metabolism in cirrhosis <b>1991</b> , 14, 432		2
11	Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by <sup>13</sup> C nuclear magnetic resonance spectroscopy. <i>New England Journal of Medicine</i> , <b>1990</b> , 322, 223-8	59.2	1052
10	Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. <i>Metabolism: Clinical and Experimental</i> , <b>1989</b> , 38, 387-95	12.7	451
9	Metabolic basis of obesity and noninsulin-dependent diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , <b>1988</b> , 4, 727-47		104
8	The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>1988</b> , 37, 79-85	12.7	235
7	Influence of hyperinsulinaemia on intracellular amino acid levels and amino acid exchange across splanchnic and leg tissues in uraemia. <i>Clinical Science</i> , <b>1988</b> , 74, 155-63	6.5	54
6	Regulation of hepatic glucose metabolism in humans. <i>Diabetes/metabolism Reviews</i> , <b>1987</b> , 3, 415-59		122
5	Announcing a new quarterly journal from Wiley, New York— <i>Diabetic Medicine</i> , <b>1985</b> , 2, 216-216	3.5	
4	Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. <i>European Journal of Endocrinology</i> , <b>1981</b> , 98, 81-6	6.5	64
3	The role of fractional glucose extraction in the regulation of splanchnic glucose metabolism in normal and diabetic man. <i>Metabolism: Clinical and Experimental</i> , <b>1980</b> , 29, 28-35	12.7	109
2	Epinephrine-induced insulin resistance in man. <i>Journal of Clinical Investigation</i> , <b>1980</b> , 65, 717-21	15.9	404
1	Mechanism of Metformin Action in Obese and Lean Noninsulin-Dependent Diabetic Subjects		1